enVVeno Medical (NASDAQ:NVNO) Stock Price Down 4.1%

enVVeno Medical Corporation (NASDAQ:NVNO) fell 4.1% during trading on Wednesday . The company traded as low as $5.10 and last traded at $5.10. 70,698 shares traded hands during trading, a decline of 22% from the average session volume of 90,648 shares. The stock had previously closed at $5.32.

enVVeno Medical Stock Performance

The company’s fifty day moving average price is $5.42 and its two-hundred day moving average price is $5.27. The firm has a market capitalization of $67.98 million, a PE ratio of -3.07 and a beta of 1.22.

enVVeno Medical (NASDAQ:NVNO) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.31) earnings per share for the quarter. On average, equities analysts expect that enVVeno Medical Corporation will post -1.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVNO. Acadian Asset Management LLC purchased a new position in shares of enVVeno Medical in the 1st quarter worth about $37,000. Quadrature Capital Ltd purchased a new position in enVVeno Medical in the first quarter valued at approximately $103,000. Fermata Advisors LLC lifted its position in enVVeno Medical by 42.1% during the first quarter. Fermata Advisors LLC now owns 23,198 shares of the company’s stock valued at $126,000 after buying an additional 6,873 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in enVVeno Medical during the first quarter worth approximately $186,000. Finally, Westside Investment Management Inc. grew its stake in enVVeno Medical by 933.7% during the second quarter. Westside Investment Management Inc. now owns 38,762 shares of the company’s stock worth $204,000 after buying an additional 35,012 shares during the period. Institutional investors and hedge funds own 34.71% of the company’s stock.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).